For the second quarter of 2026, analysts expect Grifols SA to report consensus revenue of $2.16 billion and an EPS of $0.27, with the current stock price of $8.25 trading significantly below the average analyst price target of $10.87.
Investors are primarily focused on the company’s deleveraging trajectory and its ability to generate consistent free cash flow following significant balance sheet restructuring and asset sales.
The market is also closely monitoring growth within the core Biopharma segment, specifically the immunoglobulin franchise, which remains the primary driver of top-line expansion. Sustained margin improvement and operational discipline under the new operating model are critical to restoring investor confidence after historical volatility regarding debt levels.